Chinese Biotech Firms Expand Global Licensing Deals Amid Regulatory Reforms
China's biotech sector is experiencing significant growth due to regulatory reforms and increased investment in research and development. Companies such as Sciwind Biosciences, Lepu Biopharma, 3SBio, Insilico Medicine, and Innovent Biologics are at the forefront, engaging in major licensing deals and partnerships to expand their reach beyond China. These firms are focusing on areas like oncology, metabolic diseases, and AI-driven drug discovery. Notable deals include Sciwind's $70 million licensing agreement with Verdiva Bio and 3SBio's $6 billion deal with Pfizer. These developments are part of a broader trend where Chinese companies are leveraging regulatory changes to streamline clinical trials and approvals, thus enhancing their global competitiveness.